Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $37.3333.

A number of research firms have weighed in on NBTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th. Leerink Partners raised their target price on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. UBS Group lifted their price target on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th.

Nanobiotix Trading Up 1.1%

Nanobiotix stock opened at $38.22 on Friday. Nanobiotix has a 1-year low of $6.97 and a 1-year high of $57.14. The firm has a 50-day moving average of $37.65 and a 200-day moving average of $34.01.

Institutional Trading of Nanobiotix

Hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its stake in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares in the last quarter. Marshall Wace LLP purchased a new position in Nanobiotix in the 4th quarter worth approximately $220,000. Finally, Millennium Management LLC purchased a new position in shares of Nanobiotix in the fourth quarter worth $390,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.